Btk inhibitors

Novartis' BTK inhibitor beats placebo in dermatology trial, lining up another potential indication
Fierce Biotech
Sun, 03/10/24 - 08:29 pm
Novartis
dermatology
Btk inhibitors
remibrutinib
hidradenitis suppurativa
clinical trials
Merck KGaA drops BTK inhibitor evobrutinib, marking end of road for blockbuster dreams
Fierce Biotech
Thu, 03/7/24 - 11:34 am
Merck KZGaA
Btk inhibitors
evobrutinib
Eli Lilly’s Jaypirca to dominate CLL BTK inhibitor market by 2032
Biopharma Reporter
Thu, 01/18/24 - 05:04 pm
Eli Lilly
Jaypirca
CLL
Btk inhibitors
Lilly Wins Second Accelerated Approval for Reversible BTK Inhibitor
BioSpace
Mon, 12/4/23 - 09:41 am
Eli Lilly
FDA
Jaypirca
CLL
small lymphocytic leukemia
Btk inhibitors
AbbVie's Imbruvica-Brukinsa patent suit may have merit, and BeiGene will likely settle: expert
Fierce Pharma
Tue, 06/27/23 - 10:21 pm
AbbVie
patents
BeiGene
legal
Btk inhibitors
Merck KGaA's multiple sclerosis drug hit with partial FDA hold, adding to BTK-liver injury links
Fierce Biotech
Wed, 04/12/23 - 11:52 am
Merck KGaA
multiple sclerosis
MS
Btk inhibitors
liver damage
Lilly enters ripe BTK field with quick FDA nod in mantle cell lymphoma
Endpoints
Sun, 01/29/23 - 02:14 pm
Eli Lilly
Btk inhibitors
FDA
Merck
mantle cell lymphoma
Jaypirca
EHA 2019 – turnaround puts Arqule in the takeover frame
EP Vantage
Sat, 06/15/19 - 05:47 pm
Arqule
ARQ 531
EHA
Btk inhibitors
Imbruvica resistance provides early but fertile development ground
EP Vantage
Fri, 03/15/19 - 10:43 am
Arqule
Imbruvica
drug development
Btk inhibitors
In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica
Endpoints
Tue, 01/15/19 - 10:08 am
China
FDA
Btk inhibitors
BeiGene
cancer
In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
Endpoints
Fri, 03/9/18 - 10:48 am
Eli Lilly
Merck KGaA
Btk inhibitors
autoimmune disease
evobrutinib
$690M deal in peril after Lilly ends mid-stage studies
Biopharma Dive
Wed, 02/21/18 - 09:43 am
Eli Lilly
clinical trials
rheumatoid arthritis
Btk inhibitors
Hanmi Pharmaceutical
LY3337641/HM71224
Following PhIII breakdown, AstraZeneca cruises toward an FDA decision for its BTK blockbuster hopeful acalabrutinib
Endpoints
Wed, 08/2/17 - 09:50 am
AstraZeneca
FDA
acalabrutinib
Btk inhibitors
MannKind Rents Out a Drug Program
Motley Fool
Tue, 05/1/12 - 12:37 pm
MannKind
Tolero
Btk inhibitors
Pharmacyclics Scores Big With Janssen Biotech Deal
Seeking Alpha
Mon, 12/12/11 - 10:40 am
Janssen Biotech
Pharmacyclics
Btk inhibitors